The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Lung cancer disparities in molecular testing and therapy outcome in Hispanics in Latin America
Disparities in diagnosis and clinical outcomes of Hispanic patients with lung cancer compared with Non-Hispanic White patients are well-documented, whereby Hispanics have disadvantages in terms of access to care, health insurance, cultural differences, and immigration status. Despite this, Hispanics have a better overall-survival (OS) than other minorities, which created the Hispanic Health Paradox (HHP). Luis Raez, MD, FACP, FCCP, Memorial Cancer Institute/Memorial Healthcare System, Miami, FL, discusses a review on recent publications in Hispanics, which demonstrated significant disparities in Hispanics with lung cancer care exist in the US and Latin America. Although Hispanics have a biological advantage not yet understood, the lack in biomarker access and targeted therapy as a result of social determinants of health, the potential biological benefits are eliminated. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
